Varisolve

**Varisolve** (also known as **Varithena**) is a pharmaceutical-grade polidocanol injectable foam sclerosing agent developed by **BTG plc** for the non-surgical treatment of varicose veins, specifically targeting incompetent great saphenous veins (GSV), accessory saphenous veins, and visible varicosities of the GSV system above and below the knee. The foam, generated from a proprietary low-nitrogen canister device, displaces blood in the target vein, allowing polidocanol—a non-ionic surfactant—to attach to the venous endothelium's lipid membrane, disrupt the osmotic barrier, cause endothelial destruction, vasospasm, thrombus formation, and eventual replacement by fibrous tissue. FDA-approved in 2013 as **Varithena** following successful Phase 3 VANISH-1 and VANISH-2 trials demonstrating symptom improvement and varicosity reduction, it offers a minimally invasive alternative to surgery with ultrasound-guided intravenous administration, maximum 15 mL per session, and post-treatment compression.[1][3][4][7]

Brand names

Varisolve

Other names

VarithenaVarisolve PEM